Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

Nature Medicine, Published online: 08 October 2024; doi:10.1038/s41591-024-03270-6

Individuals with Parkinson’s disease treated with prasinezumab demonstrated slower motor progression over 4 years compared with an external comparator cohort derived from the Parkinson’s Progression Markers Initiative observational study.